FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307497958> ?p ?o ?g. }

• W4307497958 endingPage "575" @default.
• W4307497958 startingPage "567" @default.
• W4307497958 abstract "Backgrounds: A new generic formulation of 3.5% lidocaine hydrochloride ophthalmic gel has been developed in China. This study aimed to evaluate the pharmacokinetics and effectiveness of this lidocaine hydrochloride gel for ocular surface anesthesia. Methods: In the pharmacokinetics study, the new form of 3.5% lidocaine hydrochloride gel or Akten™ 3.5% lidocaine hydrochloride gel was applied in eyes of 70 rabbits. The ocular tissues and plasma samples were collected after the application of 3.5% lidocaine hydrochloride gel or Akten lidocaine gel and analyzed using the liquid chromatography with tandem mass spectrometry (LC-MS/MS) method to determine the concentration of lidocaine. A multicenter, randomized, double-blind prospective clinical trial was conducted in Chinese adults. Two hundred twenty participants were 1:1 randomized into the sham gel group or the lidocaine hydrochloride group. The primary efficacy endpoint was defined as the percentage of subjects achieving anesthesia by 5 min. Results: The animal pharmacokinetics study showed the lidocaine level was significantly higher in the choroid at 15 min and the vitreous body at 15 and 30 min; it was lower in tears at 8 h for 3.5% lidocaine hydrochloride gel than Akten (P ≤ 0.05). Our clinical trial showed that the percentage of subjects achieving anesthesia within 5 min in the lidocaine hydrochloride gel group was significantly higher than the sham gel group (86.92%-18.18%, P < 0.0001). The incidence of adverse events was relatively low and favorable for both groups. Conclusion: This new formulation of lidocaine hydrochloride gel, with pharmacokinetics similar to Akten, may exert a sustained, effective, and safe anesthetic effect. The clinical trial for this new generic formulation of lidocaine hydrochloride has been registered with the Drug Clinical Trial Registration and Information Publicity Platform established by State Food and Drug Administration of China (Registration No. CTR20160593)." @default.
• W4307497958 created "2022-11-02" @default.
• W4307497958 creator A5003521760 @default.
• W4307497958 creator A5007036736 @default.
• W4307497958 creator A5024915953 @default.
• W4307497958 creator A5027876715 @default.
• W4307497958 creator A5033720641 @default.
• W4307497958 creator A5043332372 @default.
• W4307497958 creator A5045990965 @default.
• W4307497958 creator A5081331299 @default.
• W4307497958 date "2022-10-01" @default.
• W4307497958 modified "2023-09-27" @default.
• W4307497958 title "Lidocaine Hydrochloride Gel for Ocular Surface Anesthesia: Pharmacokinetic Evaluation and Randomized Placebo-Controlled Trial in China" @default.
• W4307497958 cites W1847712844 @default.
• W4307497958 cites W1969373623 @default.
• W4307497958 cites W1978516559 @default.
• W4307497958 cites W1979991651 @default.
• W4307497958 cites W2022686740 @default.
• W4307497958 cites W2052558770 @default.
• W4307497958 cites W2063171101 @default.
• W4307497958 cites W2068606204 @default.
• W4307497958 cites W2069668682 @default.
• W4307497958 cites W2080635045 @default.
• W4307497958 cites W2116788190 @default.
• W4307497958 cites W2154204321 @default.
• W4307497958 cites W2160723531 @default.
• W4307497958 cites W2185822695 @default.
• W4307497958 cites W2313664414 @default.
• W4307497958 cites W2550936658 @default.
• W4307497958 cites W2587005936 @default.
• W4307497958 cites W2769681148 @default.
• W4307497958 cites W2803793574 @default.
• W4307497958 cites W3098303647 @default.
• W4307497958 doi "https://doi.org/10.1089/jop.2022.0080" @default.
• W4307497958 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36288558" @default.
• W4307497958 hasPublicationYear "2022" @default.
• W4307497958 type Work @default.
• W4307497958 citedByCount "0" @default.
• W4307497958 crossrefType "journal-article" @default.
• W4307497958 hasAuthorship W4307497958A5003521760 @default.
• W4307497958 hasAuthorship W4307497958A5007036736 @default.
• W4307497958 hasAuthorship W4307497958A5024915953 @default.
• W4307497958 hasAuthorship W4307497958A5027876715 @default.
• W4307497958 hasAuthorship W4307497958A5033720641 @default.
• W4307497958 hasAuthorship W4307497958A5043332372 @default.
• W4307497958 hasAuthorship W4307497958A5045990965 @default.
• W4307497958 hasAuthorship W4307497958A5081331299 @default.
• W4307497958 hasConcept C112705442 @default.
• W4307497958 hasConcept C2780149897 @default.
• W4307497958 hasConcept C2910703761 @default.
• W4307497958 hasConcept C42219234 @default.
• W4307497958 hasConcept C71924100 @default.
• W4307497958 hasConcept C98274493 @default.
• W4307497958 hasConceptScore W4307497958C112705442 @default.
• W4307497958 hasConceptScore W4307497958C2780149897 @default.
• W4307497958 hasConceptScore W4307497958C2910703761 @default.
• W4307497958 hasConceptScore W4307497958C42219234 @default.
• W4307497958 hasConceptScore W4307497958C71924100 @default.
• W4307497958 hasConceptScore W4307497958C98274493 @default.
• W4307497958 hasIssue "8" @default.
• W4307497958 hasLocation W43074979581 @default.
• W4307497958 hasLocation W43074979582 @default.
• W4307497958 hasOpenAccess W4307497958 @default.
• W4307497958 hasPrimaryLocation W43074979581 @default.
• W4307497958 hasRelatedWork W1966490122 @default.
• W4307497958 hasRelatedWork W2030488188 @default.
• W4307497958 hasRelatedWork W2041330212 @default.
• W4307497958 hasRelatedWork W2059073450 @default.
• W4307497958 hasRelatedWork W2061984193 @default.
• W4307497958 hasRelatedWork W2067132729 @default.
• W4307497958 hasRelatedWork W2091822563 @default.
• W4307497958 hasRelatedWork W2366555933 @default.
• W4307497958 hasRelatedWork W2391704688 @default.
• W4307497958 hasRelatedWork W2393376173 @default.
• W4307497958 hasVolume "38" @default.
• W4307497958 isParatext "false" @default.
• W4307497958 isRetracted "false" @default.
• W4307497958 workType "article" @default.